Urushiol Patch Test System for Contact Dermatitis Assessment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for preventing and treating urushiol-induced allergic contact dermatitis from poison ivy, oak, and sumac are inadequate, with no effective sensitivity patch test available in the U.S. to assess the efficacy of therapies, and existing barrier products require preemptive use and have limitations in effectiveness.
Innovation Solution
A urushiol-containing epicutaneous patch test system comprising a support material with a urushiol-containing film, allowing for assessment of sensitivity and severity of allergic contact dermatitis, including a test panel with varying urushiol doses to evaluate treatment effectiveness.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If barrier creams are used to prevent urushiol-induced allergic contact dermatitis, then protection from developing a reaction is provided, but subjects must preemptively use these products before exposure and effectiveness is not guaranteed for all subjects
Solution Approach 1:
The patent applies preliminary action by requiring subjects to preemptively apply barrier cream containing quaternium-18-bentonite before exposure to urushiol. The barrier cream is applied in advance to create a protective layer on the skin that prevents urushiol from penetrating and causing allergic contact dermatitis.
Solution Approach 2:
The patent uses quaternium-18-bentonite as an intermediary substance between the skin and urushiol. This barrier cream acts as a mediator that blocks the interaction between urushiol and skin, preventing the allergic reaction while allowing normal skin function.
2Measurement precision
If sensitivity patch tests are conducted to assess therapy efficacy, then accurate assessment of urushiol-induced allergic contact dermatitis is enabled, but no such test was available in the U.S. to evaluate treatment effectiveness
Solution Approach 1:
The patent implements a self-service approach by enabling subjects to assess their own sensitivity to urushiol and the effectiveness of treatments through standardized patch testing. The test panels provide objective measurements that subjects can use to monitor their condition and treatment response without requiring specialized medical infrastructure.
3Reliability
If existing barrier products are used, then some protection is provided, but they have limitations in effectiveness and require preemptive application
Solution Approach 1:
The patent emphasizes preliminary application of the barrier cream before exposure to urushiol. By applying the protective barrier in advance, subjects ensure maximum protection effectiveness while maintaining the ability to engage in normal activities without concern for post-exposure treatment.
Data Source
AI summary
Disclosed herein are urushiol-containing epicutaneous patches comprising a support material and a urushiol-containing film on a surface of the support material. A surface of the support material is coated with the urushiol-containing film. Also described herein are test panels comprising urushiol-containing epicutaneous patches of varying urushiol content. The test panels can be employed in methods to assess subject sensitivity to urushiol, to determine a dose-response relationship to varying doses of urushiol, and to assess efficacy of treatments to prevent or inhibit urushiol-induced contact dermatitis in a subject.